Kintara Therapeutics, Inc. stock is down -90.72% since 30 days ago. The next earnings date is Feb 13, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 36.36% of the previous 10 November’s closed higher than October.
Kintara Therapeutics, Inc. focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell Val-083 in China.